Acumen Pharmaceuticals shares are trading lower. The company highlighted enhanced brain delivery program data and early Alzheimer’s disease insights at Alzheimer’s AAIC 2026.

Benzinga Newsdesk www.benzinga.com Positive 45.6%

Neg 0% Neu 0% Pos 45.6%

Comments

No comments yet. Be the first!